A B S T R A C T Patients with gyrate atrophy of the choroid and retina have 10-to 20-fold increased ornithine concentrations in body fluids and significantly reduced activity of ornithine aminotransferase in lymphocytes and cultured fibroblasts. We administered intravenous arginine to six patients and six controls to study in vivo inhibition by high ornithine concentrations of arginine-glycine transamidinase, the ratelimiting enzyme in creatine synthesis. Serum arginine concentration curves after administration were similar for the two groups. The increment in serum ornithine was more than three times as great in patients as in controls. The mean half-times in plasma omithine were 360 and 97 min, respectively. In the patients, the metabolic clearance of ornithine from the extracellular fluid was significantly delayed. Urinary guanidinoacetate excretion rose markedly in all controls, the excretion rate being higher in females. The patients always excreted less than the controls, the differences within the sexes being highly significant. Differences in creatine excretion after administration were less marked.
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We conclude that in gyrate atrophy patients, formation of guanidinoacetate, creatine, and possibly phosphocreatine is inhibited at the transamidination step by the high concentrations of omithine. Deficiency of the high-energy phosphates may underlie the pathogenesis of the eye and muscle atrophies.
INTRODUCTION
Gyrate atrophy ofthe choroid and retina is an autosomal recessive tapetoretinal dystrophy that begins clinically by the age of 5-9 yr as night blindness, myopia, and constriction of the visual fields (1). Patchy atrophic areas appear at the midperiphery ofthe ocular fundi and spread towards the optic disc. The visual fields narrow down to practical blindness by age 20-40 yr, progression being faster in males. The patients are otherwise healthy but rapid muscular performance may be subnormal for age. The number of type II muscle fibers is decreased, and parts of the remaining fibers contain atrophic areas, seen in electron microscopy to be filled with tubular aggregates (2) . Among the tapetoretinal dystrophies gyrate atrophy is not uncommon, for numerous cases have been reported from several countries. However, our 41 Finnish homozygous patients seem to represent a concentration in a population of 4.7 million.
In 1973 we found 10-to 20-fold increases in ornithine concentration in the body fluids of these patients (3) . Lymphocytes and fibroblast cultures confirmed a deficiency of the main catabolic enzyme of ornithine, ornithine ketoacid transaminase (ornithine transaminase, EC 2.6.1.13) in these patients (4) (5) (6) (7) . However, the mechanism of the tapetoretinal and muscular atrophy in the disease is obscure. Ornithine per se obviously is not the cause, as ornithine concentration is similarly increased in another disease without any eye or muscle changes (8) . Arginine-glycine amidinotransferase (EC 2.1.4.1.), the rate-limiting enzyme in creatine production, is effectively inhibited by ornithine in rat kidney (9) . To investigate this inhibition in vivo we administered arginine intravenously to patients with gyrate atrophy and found subnormal formation of guanidinoacetate, suggesting failure of creatine and subsequent phosphocreatine production as the cause of atrophy in the muscles and eyes.
METHODS
Experimental. 1 were measture(I dturinig a 0.5-2-h infrisioni of 5%imannitol, 12 inl/kg per h. Adequiate d(iuresis after the argininie admiinlistration was ensuire(l l)y giving a similar infusioni of manniitol for 4-6 h. Plasmnca samiiples for meassuremiienit of amino acids were takeni at 15-30-min intervals for 4-6 h, andl turine was collected in 30-mii periodls l)y voiding. Two mncale patienits were unal)le to voidi at the expected intervals; for themn, longer collection periodIs were usedl. The subjects remcainied in l)ed for the first 4 h andl were then allowedl to move. All subjects hcadc given informiiedl consenit to the experiment, ancI they all remiainedl symptomii-free (lurinig the test.
Autali tical. Plasmiia and turiniarv aiiiino acids were imieasured with a Beckman 121 MI amino acid analyzer (Beckman Instrumilenits, Inc., Fullerton, Calif.), and serum urea, creatiniime, andl glticose by routine methlodls. Sertumii creatinie was ImleasureI l)y repeatinig the Jaffe creatininie miieassuremiient after aci(d hvdrolysis. For quianititation of uirincarv gianiidinoacetate, 50-mIl portionis of collections were deproteinized bw acidification and(I the suipernate lyophilizecl. The pellet was suispenlded in 99.5% alcohol to remove the manniiiitol, aind the superniate relyophilized anid s;uspendled in 1.5 ml of 0.1 NM citrate buffer, pH 3.5. A 1-mnl portion was pipettedl onto a 19 x 0.9-cmii coltullmln, packed with Beckmani Spherical Ion Exchange Resin, type M181. The gtuanidlinio derivatives were eltute(d with 0.1 MI citrate buffer, 50 mnl/h, pH 3.5. 4-mIl fractions were collected, andl guianidinioacetate (fractionis [35] [36] [37] andl creatine (fractions 17-19) were miieasiure(d 1w the VogesProskauter reaction. The recoveries of'creatine aIindI gtuanidinioacetaite were 90 anid 85%, respectively.
RESULTS
The fasting plasmna arginine concentration (mean ± SD) in patients with gyrate atrophy (83.4±27.9,mol/liter) did not differ significantly fromn the controls (72.5±12.8
Amnol/liter). Arginine infusion causedl ain e(ual rise in plasmia arginine in the two groups (Fig. 1) . The hyperbolic disappearanice curves were also simiiilar, and in 1)oth groups at 6 h after the infusion, imiean plasma arginine was still threefold higher than (luring fasting. Urinary arginiine excretion behaved like the plasia curves, with two differences. In the basal state the patients excreted signiificantly more than the controls, au(i their excretion returned to the starting levels later (Table I) . Thus during the 6-h collection period the patients lost imore of the load into the urine (17.3±3.1%) than did the control subjects (10.1±3.5%).
Characteristically, the meean plasmia orniitlhine concentration (Ilurinig fasting was 19.7 timnes as higlh in patienits as in controls (Table I) . After the argininie inftusioni, plasmiia ornithine peaked in both grouips at 30-45 min. The molar inerement in the patienits was imore than three times that in the coontrols. The disappearance etrves from the plasma of patienits anid cointrols apparently initially followed first order kineties, b)ut in the controls a change was seen after 210 min, i.e., slightly before the starting plasm-a concenltration was reached. The half-timiies for ornithine in plasmiia durinig the period of first order kinetics were 360 min (K = 0.0019) aind 97 mmin (K = 0.0071) in patients and controls, respectively. In the controls, plasmiia arginiiie was conisistenitlv far above ornithlinie, but in the patients arginine concenitrationi exceeded ornithine only at the 15-min meassuremienit, i.e., immilediately after the argininie infusion. Even d(urinig faisting the patients lost large amiiounts of ornithlinie into the urine but the argininie infusion led to miiassive ornithinuria, which in molar units accounited for a signiificant part of the aminiiio acid infused (Table I ). In the conitrols ornithlinle exeretion was only slightly increased by the load. The ornithine conicenitration needed for equial di sappearance rate of the extracellular fluid ornithinie was 5-10 tim11es as high in the patients as in the controls. However, the disappearance rate of ornithine in the patients exceeded clearly the acmount excreted into the urine.
Guanidinoacetate was constantly excreted into the urine by the controls, but only negligible ami-ounts were detectable in the urine of the patients (Fig. 2) . After the infusion, guanidinoacetate excretion increased rapidly in both groups. However, the rise in the patients was only a fraction ofthat in the conitrols, in whom the excretion rate was continuously 10-to 20-fold higher. In both groups urinary guan idinoacetate excretion was imore rapid in the femn-ales. For plasmla creatine, changes after the load were insignificant in all test subjects. Urinary creatine excretion seemed to be sex dependent, the females again having higlher vallues. After the infusioni, most controls had a brief peak in creatine excretion (Fig. 3) . In the patients, either the peak was delayed and less mlarked, or excretion did niot change at all. The values for patients and controls clearly overlapped.
DISCUSSION
Gucaniidin-oacetate excretion in patienits with gyrate atrophy of the choroid aind retina was significanitly slower than in conitrols, both during fasting aind after an infuLsion of arginine. Even after an unplhysiologic arginine infu,sion, the concentration of arginine in the Argintine Metabolism itn Gyrate Atrophly patients only temporarily exceeded that of ornithine in the plasmn-a and presumal)ly elsewhere in the body. Thus, one product of the actioni of arginine-glycine amiiidiino-transferase was constantly present in abnormnally high concentrations. We have shown that this amicidino-transferase is competitively inhibited by ornithine, with an inhibition constant for ornithine in rat ime, h kidney homegenate of 0.253 mM (9) . Our present results show that endogenous ornithine is also an effective inhibitor of guanidinoacetate production in man in vivo: the activity of the enzyme, which is rate-limiting for the vital synthesis of creatine, is also effectively controlled by creatine concentrationi via an endproduct negative feedback inhibition, as both endogenous anid exogenous creatine quickly repress transamnidiniase activity (10) . We suggest that in patients with gyrate atrophy the inadequiate guanidinoacetate productioni aind fuirther deficiency of creatine and phosphocreatine mncay be linked directly with the eye and miuscle atrophies. In another disease with similar plasmiia ornithinle concentrations, the transport of ornithine into the mlitochondria is probably defective (11) and intramitochonidrial ornithine concentration remains normal. In this situation the intracmitochondrially located L-arginineglycine amidinotransferase would not be inhibited by ornithine and endogenous creatinie synthesis would not be restricted.
We did not find a good correlation l)etween the excretion rates of guanidinoacetate, the rate limniting comilponeint of the creatinie synthesizing reactioni, acndl of creatine, although the patients, if comipared with controls of their ownl sex, showed a clear tendency to low rates of creatine excretioni. The guaniidinoacetate formned is miethylalted effectively (12) and the creatinie formned is rapidly trapped by the muscles (13) . Thus both serumil and urinary creatine concentrations probably better reflect the creatinie lost from the muscles either durinig normlal renovation of creatine stores, or ats result of patlhologic leakage, as in some myopalthies or after tratum-a.
The five-carbon unit of argininie is mainly incorporated into proteins, recycled in the urea cycle, used in the synthesis of (luanititatively unimilportaint amiiouniits of polyamiiines, or (legraded( via ornithinle, milainily through the ornithine ketoacid aiiiino tranisferase. This enzymne is deficient in patients with gyrate atrophy. In the present experimients, the bulk of the argininle was rapidly converted into ornithine in both patieints and controls. The metabolic clearance rate ofornithine from plasmna and extracellular fluid was significantly re-(luced in the patients (Table I andl Fig. 1 ). Because no other important routes for ornithine catabolism are known, our findings imply that the ornithiine ketoacidl aimiinotransferase in the pa'tients functions efficiently at these elevated ornithine concentrations.
Becatuse an arginine load in the patients seems to lead to a higher than normnal increase in ornithine, any attemipt to improve guanidinioacetate acnd creatine synthesis by feeding extra arginine to these patients seems to be inefficient, if not deleterious. If our hypothesis is valid, i.e., if deficient guanidinoacetate synthesis is the mechanism of the eye and musele changes, two approaches remain for treatment of these patients. Stringent restriction of all protein in the diet would presumably result in a decrease in ornithine concentration and allow the arginine-ornithine ratio to revert to normal, so tendinig to normiialize creatinie prodtuction. Oni the other haind, exogenous creatine couild be efficiently acdmiiistere(l to the patients aind wouldl leadl to a(le(luzate availabilitv of the creatinie moietv in the mutiseles and(I eves, whielh are assumed to be critically dlependlenit for their energy suipply on1 phosphocr-eatinie.
